TZDs, Thiazolidinediones

Thiazolidinediones (TZDs) are potent synthetic agonists of PPARy and medicine for type 2 diabetes. TZDs were shown to induce neuroprotection after cerebral ischemia by blocking inflammation (Culman et al., 2007). Spinal cord injury (SCI), another type of neurodegenerative disease, also induces massive inflammation that precipitates secondary neuronal death. Park et al. (2007) analyzed the therapeutic efficacy of TZDs, pioglitazone, and rosiglitazone, after SCI 

Fig. 19 Primary structural requirements of thiazolidinediones (TZDs) for PPARy agonistic activity

TRPV1 receptors and PKRs, 152 True Lavender (Lavandula angustifolia), 241 Tumor necrosis factor-a (TNF—a), 180 TZDs. See Thiazolidinediones 

PAOP pulmonary artery occlusion pressure P-gp P-glycoprotein RAA renin-angiotensin-aldosterone RVF right ventricular failure SDC serum digoxin concentration S VR systemic vascular resistance TNF-a tumor necrosis factor-a TZD thiazolidinedione VAD ventricular assist device 

Analysis Pioglitazone, the active ingredient in Actos, is a member of the thiazolidinedione (TZD) molecular class and has the structure (1)  

---